home / stock / bctxw / bctxw news


BCTXW News and Press, BriaCell Therapeutics Corp. Warrant

Stock Information

Company Name: BriaCell Therapeutics Corp. Warrant
Stock Symbol: BCTXW
Market: NASDAQ
Website: briacell.com

Menu

BCTXW BCTXW Quote BCTXW Short BCTXW News BCTXW Articles BCTXW Message Board
Get BCTXW Alerts

News, Short Squeeze, Breakout and More Instantly...

BCTXW - BriaCell to Present Four Poster Presentations at the 2026 AACR Annual Meeting

PHILADELPHIA and VANCOUVER, British Columbia, March 10, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care...

BCTXW - BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

PHILADELPHIA and VANCOUVER, British Columbia, March 05, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX , BCTXL ) (TSX:BCT) (“BriaCell” or the “Company”) , a clinical-stage biotechnology company that develops novel immunotherapies to transform can...

BCTXW - BriaCell and BriaPro Enter Into Asset Purchase Agreement for Exclusive Soluble CD80 License

PHILADELPHIA and VANCOUVER, British Columbia, Feb. 18, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ, BCTXL) (TSX: BCT) (“ BriaCell ”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, and its maj...

BCTXW - BriaCell Patients' Images Show Regression and Resolution of Metastasized Tumors and Immune Activation

Images below confirm clinical responses seen in patients with metastatic orbital (eye), temporal (brain), liver, and spine lesions No Bria-IMT™ related discontinuations reported to date Bria-IMT regimen continues under Fast Track Designation from US FDA PHILADELPHIA a...

BCTXW - BriaCell Highlights Extended >18-47 Months Survival in Phase 2 Metastatic Breast Cancer Patients

9 of 25 BriaCell patients treated since 2022   remain alive >18-47 months post enrollment, markedly exceeding benchmarks reported for standard of care therapies in similar patient populations No Bria-IMT™ related discontinuations reported to date Bria-IMT regimen...

BCTXW - BriaCell Therapeutics Announces Closing of US$30 million Public Offering

PHILADELPHIA and VANCOUVER, British Columbia, Jan. 15, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer ca...

BCTXW - BriaCell Therapeutics Announces Pricing of $30 million Public Offering

PHILADELPHIA and VANCOUVER, British Columbia, Jan. 13, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer ca...

BCTXW - BriaCell Reports Sustained Complete Resolution of Lung Metastasis in Bria-OTS(TM) Patient

[IMAGES BELOW] 11-month sustained complete resolution of lung metastasis observed in Bria-OTS Phase 1/2a metastatic breast cancer study. No treatment limiting toxicities reported. Patient maintained stable disease at all other evaluable sites. PHILADELPHIA and VANCOUVER, British...

BCTXW - "Eleven clinical trials that will shape medicine in 2026" - BriaCell Phase 3 Trial Featured in Nature Medicine

Nature Medicine asked leading researchers to name their top clinical trial for 2026, from long-awaited vaccines for infectious diseases to new treatments for advanced cancers and long COVID BriaCell’s Phase 3 clinical trial in metastatic breast cancer featured as “clinical tria...

BCTXW - BriaCell Presents Outstanding Phase 2 Survival & Promising Phase 3 Clinical Data at SABCS® 2025

BriaCell presents positive clinical data in three posters at the San Antonio Breast Cancer Symposium (SABCS ® ) Phase 3 study of Bria-IMT™ plus immune check point inhibitor (CPI) continues to support biomarkers to identify patients who benefit from treatment with BriaC...

Next 10